focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Share News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.80
Bid: 3.50
Ask: 4.50
Change: 0.49 (13.96%)
Spread: 1.00 (28.571%)
Open: 3.80
High: 3.80
Low: 3.80
Prev. Close: 3.51
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Proteome Appoints Geoffrey Ellis As Finance Director, Loss Widens

Tue, 30th Sep 2014 09:41

LONDON (Alliance News) - Proteome Sciences PLC said Tuesday that has appointed Geoffrey Ellis as Finance Director, and posted a slightly widened pretax loss for the half-year to the end of June.

Ellis previously acted as chief financial officer of The Walt Disney Co's Network of Disney Channels in Europe, the Middle East and Africa, and managing director Disney Channel Scandinavia, Middle East and Emerging Markets.

Ellis succeeds James Malthouse, who is retiring after 20 years with the company.

Proteome posted a pretax loss of GBP2.1 million, widened from a loss of GBP1.9 million a year before, as revenue declined to GBP784,276 from GBP885,475, and administrative expenses rose slightly to GBP2.5 million from GBP2.3 million.

The company said following the growth in licensing, services and sales of its Tandem Mass Tag reagents in 2013, its core technologies had continued to strengthen in the first-half of 2014. Some contracts it was expecting were delayed, however, and the company said because of their size it is difficult to predict when they will come through.

Proteome said that whilst it is "difficult to be precise" over the timing of these revenue contributions, the scale and number of contracts in its order book is "growing steady and that performance is expected to continue in 2015."

Sales of Tandem Mass Tag reagent's rose 98% compared to the previous year. Proteome expects to see a more significant contribution from the products in the second-half, as well as continued improvement in its revenues from licences, sales and services.

Last Friday the company announced "excellent" results from in vitro toxicity tests for its two lead compounds to treat Alzheimer's disease, which it hopes will attract pharmaceutical companies to partner with Proteome on the treatments.

Shares in Proteome are trading down 8.0% at 35.18 pence Tuesday morning.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
23 Jun 2015 13:26

Proteome raises £2.5m from placing

Protein biomarker company Proteome Science has placed 13.86m shares at 18p each, raising £2.5m before expenses. The proceeds will be used to increase capacity and shorten lead times ensuring the company can continue to meet the significant increase in demand for its biomarker services from a growing

Read more
23 Jun 2015 06:59

Proteome Sciences Raises GBP2.5 Million In Share Placing (ALLISS)

Read more
29 May 2015 08:01

Proteome Sciences Says It Has Seen "Good Start" To 2015, Loss Widens

Read more
9 Mar 2015 08:40

Proteome Sciences Sees Good Start To 2015 On Contract Signings

Read more
12 Nov 2014 13:06

UK MIDDAY BRIEFING: RBS, HSBC Hit With Fines, Barclays Still In Talks

Read more
12 Nov 2014 12:02

UK WINNERS & LOSERS: G4S And Tullow Oil Lead FTSE 100 Gainers

Read more
12 Nov 2014 12:00

Proteome slides after warning on revenues

Shares in Proteome fell sharply on Wednesday after the group warned its revenue for the current year will be lower than market expectations and "somewhat" lower than the revenues achieved in 2013. The protein biomarker group explained that it had seen a continuation of the previously flagged delay t

Read more
12 Nov 2014 09:27

Proteome Says Revenue Will Not Meet Market Expectations

Read more
26 Sep 2014 07:21

UK MORNING BRIEFING: De La Rue, Shanks Issue Profit Warnings

Read more
26 Sep 2014 07:03

Proteome Sees "Excellent" Toxicity Test Results For Alzheimer's Drugs

Read more
25 Sep 2014 15:29

Proteome Sciences wins $2m biomarker deal

teerngasAIM biotech Proteome Sciences has been signed up to provide to develop diagnostic products for Alzheimer's disease group Genting TauRx Diagnostic, worth $2m in upfront and milestone payments. Proteome's biomarker services division will analyse blood samples from patients enrolled in a phase

Read more
25 Sep 2014 12:15

REPEAT: UK MIDDAY BRIEFING: Glaxo Appoints Philip Hampton As Next Chairman

Read more
25 Sep 2014 12:09

UK MIDDAY BRIEFING: Glaxo Appoints Ex-RBS Head As Non-Exec Chairman

Read more
25 Sep 2014 11:43

UK WINNERS & LOSERS: 5G Deal Boosts Vodafone Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.